Zenas BioPharma (NASDAQ:ZBIO) Trading Up 7.9% – What’s Next?

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) rose 7.9% on Thursday . The stock traded as high as $23.66 and last traded at $23.5250. Approximately 259,533 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 807,108 shares. The stock had previously closed at $21.80.

Analysts Set New Price Targets

Several research firms recently commented on ZBIO. Guggenheim raised their target price on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Wednesday. Morgan Stanley lifted their price objective on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.29.

Zenas BioPharma Trading Up 4.9%

The business has a fifty day moving average of $19.33 and a 200-day moving average of $23.45. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The company has a market capitalization of $1.63 billion, a P/E ratio of -3.05 and a beta of -0.71.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter in the prior year, the business posted ($0.80) EPS. Analysts anticipate that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current fiscal year.

Insider Activity

In other Zenas BioPharma news, Director Hongbo Lu bought 3,768 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was bought at an average cost of $18.63 per share, with a total value of $70,197.84. Following the completion of the transaction, the director directly owned 426,736 shares in the company, valued at approximately $7,950,091.68. The trade was a 0.89% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Fairmount Funds Management Llc bought 150,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the director directly owned 2,359,025 shares in the company, valued at $47,180,500. The trade was a 6.79% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 273,768 shares of company stock worth $5,150,198 over the last three months. 22.00% of the stock is currently owned by insiders.

Institutional Trading of Zenas BioPharma

Institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP lifted its holdings in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma during the third quarter worth $30,000. GF Fund Management CO. LTD. bought a new stake in Zenas BioPharma during the fourth quarter worth $38,000. BNP Paribas Financial Markets grew its holdings in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after buying an additional 1,716 shares in the last quarter. Finally, CWM LLC raised its position in Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after buying an additional 709 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.